CureMeta is a Boston-based privately funded biotech company dedicated to developing novel immunology therapeutics for aggressive and metastatic cancers.
Our approach to curing cancer is different. Our drug development strategy is passionately driven by the hypothesis that metastatic and aggressive cancers are caused by “reprogramming” of a “stressed” cell backwards to a primitive, embryonic-like stem cell state. The CureMeta product engine has generated numerous antibodies highly specific to novel embryonic cancer targets. CureMeta’s lead drug in our pipeline, Bstrongximab-ADC, has strong and convincing preclinical data and our next step is clinical proof-of-concept in metastatic cancer patients.